Myriad Genetics Stock’s Direction Hangs on Psychiatric Debate - Barron's

Submitted by Anonymous (not verified) on Sat, 02/09/2019 - 00:26

Myriad Genetics Stock’s Direction Hangs on Psychiatric Debate  Barron'sThe genetic testing outfit's new product aims to steer doctors to the right antidepressant for patients. But some researchers question its effectiveness, particularly ...